Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap)  (beta) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer) Overgo Probe Designer
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:transition element coordination entity
go back to main search page
Accession:CHEBI:33861 term browser browse the term
Synonyms:related_synonym: transition element coordination entities;   transition metal coordination compounds;   transition metal coordination entities


show annotations for term's descendants           Sort by:
cisplatin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 multiple interactions EXP Cisplatin inhibits the reaction [ABCB1 protein results in increased susceptibility to NSC73306] CTD PMID:24800945 NCBI chr 9:93,049,955...93,146,469 JBrowse link
G AIFM1 apoptosis inducing factor mitochondria associated 1 affects response to substance EXP AIFM1 protein affects the susceptibility to Cisplatin CTD PMID:15983031 NCBI chr  X:106,676,596...106,708,290
Ensembl chr  X:106,670,520...106,708,317 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator multiple interactions
affects localization		 EXP Bezafibrate inhibits the reaction [Cisplatin affects the localization of BAX protein] CTD PMID:16316343 NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140 		JBrowse link
G CASP2 caspase 2 increases expression EXP Cisplatin results in increased expression of CASP2 CTD PMID:12712633 NCBI chr18:6,946,432...6,966,088
Ensembl chr18:6,941,937...6,966,061 		JBrowse link
G CASP3 caspase 3 increases expression
multiple interactions
increases activity		 EXP Cisplatin results in increased expression of CASP3
[Cisplatin co-treated with EPO protein] results in increased cleavage of CASP3 protein; Bezafibrate inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein]; Cilastatin inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]; Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein		 CTD PMID:12712633 PMID:16316343 PMID:20435919 PMID:21497595 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213 		JBrowse link
G CASP8 caspase 8 increases activity
increases expression
multiple interactions		 EXP Cisplatin results in increased activity of CASP8 protein
Cisplatin results in increased expression of CASP8
Cilastatin inhibits the reaction [Cisplatin results in increased activity of CASP8 protein]		 CTD PMID:12712633 PMID:20435919 NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468 		JBrowse link
G CASP9 caspase 9 increases expression
increases activity		 EXP Cisplatin results in increased expression of CASP9
Cisplatin results in increased activity of CASP9 protein		 CTD PMID:12712633 PMID:20435919 NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007 		JBrowse link
G CYCS cytochrome c, somatic affects localization
multiple interactions		 EXP Cisplatin affects the localization of CYCS protein
Bezafibrate inhibits the reaction [Cisplatin affects the localization of CYCS protein]		 CTD PMID:16316343 NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866 		JBrowse link
G EPO erythropoietin multiple interactions EXP [Cisplatin co-treated with EPO protein] results in increased cleavage of CASP3 protein CTD PMID:21497595 NCBI chr 3:8,620,508...8,622,936
Ensembl chr 3:8,620,508...8,622,936 		JBrowse link
G FAS Fas cell surface death receptor increases expression EXP Cisplatin results in increased expression of FAS mRNA CTD PMID:20435919 NCBI chr14:100,927,305...100,954,781
Ensembl chr14:100,927,089...100,956,716 		JBrowse link
G FASLG Fas ligand multiple interactions
affects localization		 EXP Cilastatin inhibits the reaction [Cisplatin affects the localization of FASLG protein] CTD PMID:20435919 NCBI chr 9:115,068,314...115,075,147
Ensembl chr 9:115,068,090...115,076,464 		JBrowse link
G GCLC glutamate-cysteine ligase catalytic subunit multiple interactions EXP Buthionine Sulfoximine inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of GCLC protein]]; sulforaphane inhibits the reaction [Cisplatin results in decreased activity of GCLC protein] CTD PMID:20732396 NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530 		JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor multiple interactions
increases expression		 EXP Acetylcysteine inhibits the reaction [Cisplatin results in increased expression of MYC] CTD PMID:12712633 NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,122...12,461,078 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP Dicumarol inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein]]; sulforaphane inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein] CTD PMID:20732396 NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases activity
multiple interactions		 EXP Cisplatin results in increased activity of PARP1 protein
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Cisplatin results in increased activity of PARP1 protein]		 CTD PMID:25806124 NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196 		JBrowse link
G PPARA peroxisome proliferator activated receptor alpha decreases activity
multiple interactions		 EXP Cisplatin results in decreased activity of PPARA protein
[Cisplatin results in decreased activity of PPARA protein] which results in increased abundance of Fatty Acids, Nonesterified; Bezafibrate inhibits the reaction [[Cisplatin results in decreased activity of PPARA protein] which results in increased abundance of Fatty Acids, Nonesterified]; Bezafibrate inhibits the reaction [Cisplatin results in decreased activity of PPARA protein]		 CTD PMID:16316343 NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239 		JBrowse link
G TNF tumor necrosis factor increases expression EXP Cisplatin results in increased expression of TNF mRNA CTD PMID:20435919 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416 		JBrowse link
G TP53 tumor protein p53 increases expression
multiple interactions		 EXP Cisplatin results in increased expression of TP53
mangostin inhibits the reaction [Cisplatin results in increased expression of TP53]		 CTD PMID:12712633 PMID:20603111 NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818 		JBrowse link
cyanocob(III)alamin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CAT catalase multiple interactions EXP [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein CTD PMID:29129240 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452 		JBrowse link
G DNMT1 DNA methyltransferase 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA CTD PMID:28445388 NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844 		JBrowse link
G DNMT3A DNA methyltransferase 3 alpha multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA CTD PMID:28445388 NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087 		JBrowse link
G GPX1 glutathione peroxidase 1 multiple interactions EXP [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA CTD PMID:29129240 NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433 		JBrowse link
G MTHFR methylenetetrahydrofolate reductase multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA CTD PMID:28445388 NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820 		JBrowse link
G SI sucrase-isomaltase multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA CTD PMID:28445388 NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478 		JBrowse link
G SLC15A1 solute carrier family 15 member 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA CTD PMID:28445388 NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933 		JBrowse link
G SLC5A1 solute carrier family 5 member 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA CTD PMID:28445388 NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841 		JBrowse link
G SOD1 superoxide dismutase 1 multiple interactions EXP [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA CTD PMID:29129240 NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729 		JBrowse link
ferroheme b term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HMOX1 heme oxygenase 1 increases metabolic processing
multiple interactions		 EXP HMOX1 protein results in increased metabolism of Heme
[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide; chromium mesoporphyrin inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]; tin protoporphyrin IX inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]		 CTD PMID:16751286
heme b term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HMOX1 heme oxygenase 1 increases metabolic processing
multiple interactions		 EXP HMOX1 protein results in increased metabolism of Heme
[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide; chromium mesoporphyrin inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]; tin protoporphyrin IX inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]		 CTD PMID:16751286
potassium chromate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GAPDH glyceraldehyde-3-phosphate dehydrogenase decreases activity EXP potassium chromate(VI) results in decreased activity of GAPDH protein CTD PMID:26582256 NCBI chr 5:64,129,678...64,135,194
Ensembl chr 5:64,129,679...64,133,991 		JBrowse link
potassium hexacyanoferrate(3-) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NOS3 nitric oxide synthase 3 decreases activity EXP potassium ferricyanide results in decreased activity of NOS3 protein CTD PMID:8810647 NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943 		JBrowse link
ruthenium red term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G TRPV1 transient receptor potential cation channel subfamily V member 1 multiple interactions EXP Ruthenium Red inhibits the reaction [Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]] CTD PMID:18230619 NCBI chr12:49,676,536...49,709,634
Ensembl chr12:49,677,291...49,713,977 		JBrowse link
sodium dichromate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AKT1 AKT serine/threonine kinase 1 decreases expression EXP sodium bichromate results in decreased expression of AKT1 protein CTD PMID:12760830
tris(picolinato)chromium term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G INS insulin decreases expression EXP chromium tripicolinate results in decreased expression of INS protein CTD PMID:7628956 NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 5007
    chemical entity 5007
      molecular entity 5006
        transition element molecular entity 195
          transition element coordination entity 33
            chromium coordination entity + 3
            cobalt coordination entity + 9
            copper coordination entity + 0
            gold coordination entity + 0
            heteropolyacid macromolecule + 0
            iron coordination entity + 2
            manganese coordination entity + 0
            metallocene + 0
            molybdenum coordination entity + 0
            osmium coordination entity + 0
            platinum coordination entity + 18
            rhenium coordination entity + 0
            ruthenium coordination entity + 1
            silver coordination entity + 0
            titanium coordination entity + 0
            transition element oxoacid + 0
            transition element oxoanion + 2
            tungsten coordination entity + 0
            uranium coordination entity + 0
            vanadium coordination entity + 0
            zirconium coordination entity + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 5007
    subatomic particle 4998
      composite particle 4998
        hadron 4998
          baryon 4998
            nucleon 4998
              atomic nucleus 4998
                atom 4998
                  group 4986
                    polyatomic entity 4986
                      heteroatomic molecular entity 4957
                        coordination entity 158
                          transition element coordination entity 33
                            chromium coordination entity + 3
                            cobalt coordination entity + 9
                            copper coordination entity + 0
                            gold coordination entity + 0
                            heteropolyacid macromolecule + 0
                            iron coordination entity + 2
                            manganese coordination entity + 0
                            metallocene + 0
                            molybdenum coordination entity + 0
                            osmium coordination entity + 0
                            platinum coordination entity + 18
                            rhenium coordination entity + 0
                            ruthenium coordination entity + 1
                            silver coordination entity + 0
                            titanium coordination entity + 0
                            transition element oxoacid + 0
                            transition element oxoanion + 2
                            tungsten coordination entity + 0
                            uranium coordination entity + 0
                            vanadium coordination entity + 0
                            zirconium coordination entity + 0
paths to the root